Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $60.00 at Stifel Nicolaus

Definium Therapeutics (NASDAQ:DFTX) had its price objective raised by stock analysts at Stifel Nicolaus from $30.00 to $60.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 34.89% from the stock’s previous close.

Several other research analysts also recently issued reports on the company. Piper Sandler restated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research report on Friday, May 8th. Canaccord Genuity Group set a $58.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, June 30th. Robert W. Baird upped their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. Finally, Needham & Company LLC increased their price target on Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $49.23.

Definium Therapeutics Stock Up 0.3%

DFTX opened at $44.48 on Wednesday. Definium Therapeutics has a one year low of $7.54 and a one year high of $49.20. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The stock has a market capitalization of $4.43 billion, a P/E ratio of -17.86 and a beta of 2.20. The business’s 50-day simple moving average is $27.65 and its 200-day simple moving average is $21.01.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Analysts anticipate that Definium Therapeutics will post -2.29 EPS for the current year.

Insider Activity

In related news, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,096 shares of company stock valued at $2,165,763 in the last 90 days. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Definium Therapeutics during the third quarter valued at $107,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Definium Therapeutics in the fourth quarter valued at about $117,000. Finally, Caxton Associates LLP acquired a new stake in Definium Therapeutics during the 3rd quarter valued at approximately $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.